We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Drug Developers Urged to Adopt Humans as Superorganism Approach

By LabMedica International staff writers
Posted on 26 Jul 2012
A recent review article summarized more than 100 studies relating to the concept that humans are actually “superorganisms” composed of many varieties of eukaryotic and prokaryotic cells.

Most drug development activities have been conducted within a framework that links a single drug with its critical receptor target. More...
However, this approach may change due to increasing interest in understanding the properties of traditional Chinese medicines (TCMs) for their potential utilization as a source of new drugs, since emerging evidence indicates that most TCM drugs are actually targeting both the human host and many of its symbiotic microbes.

Chinese medicine traditionally viewed humans as “superorganisms” comprised of only about 10% human cells with the other 90% of the body being composed of bacterial, fungal, and other cells. These symbiotic microorganisms release molecular signals that can determine whether human genes turn on or off and that can influence the immune system's defenses against disease.

To better understand the superorganism concept investigators at Shanghai Jiao Tong University (Shanghai, China) reviewed more than 100 studies related to this topic in a paper that was published in the July 6, 2012, issue of the Journal of Proteome Research. In this review, they explored the challenges of and opportunities for harmonizing Eastern–Western drug discovery paradigms by focusing on emergent functions at the whole body level of humans as superorganisms.

“This superorganism view of the human body provides a complete new systems concept for managing human health at the clinically relevant whole body level,” said the authors. “It is one of the most significant paradigm shifts in modern medicine."

The review described how this revolutionary change is fostering emergence of an approach called "functional metagenomics" for developing new medicines. This could lead to new drug candidate compounds for chronic diseases targeting receptors outside the currently accepted “druggable genome” and shed light on current high interest issues in Western medicine such as drug-drug and drug-diet-gut microbial interactions that will be crucial in the development and delivery of future therapeutic regimes optimized for the individual patient.

Related Links:

Shanghai Jiao Tong University





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Immunofluorescence Analyzer
IFA System
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.